Umoja Biopharma
Umoja Biopharma Raises $100M in Series C
Umoja Biopharma Raises $100M in Series C
Umoja Biopharma has successfully raised $100M in a Series C at a $800M valuation led by DCVC Bio, Double Point Ventures.
Company Overview
Umoja Biopharma is a HealthTech company headquartered in Seattle, WA, founded in 2019 with 100+ employees.
Cell therapy for cancer
Fundraising Details
- Amount Raised: $100M
- Round Type: Series C
- Valuation: $800M
- Date: 2025-01-01
- Investors: DCVC Bio, Double Point Ventures
About Umoja Biopharma
Cell therapy for cancer The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Seattle, WA
- Founded: 2019
- Team Size: 100+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in Umoja Biopharma's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Umoja Biopharma's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $800M valuation marks an important milestone for Umoja Biopharma, positioning the company among notable players in the HealthTech industry.
Looking Ahead
With this new capital, Umoja Biopharma is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2025-01-01. For more information about Umoja Biopharma, visit their headquarters at Seattle, WA.
Company Info
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free